11/14/2011 8:20:21 AM
Boehringer Ingelheim said that 260 cases of fatal bleeding have been linked to its new stroke prevention pill Pradaxa so far, adding that the risk of death was still below the rate that emerged in the clinical trial that led to the drug's approval. In early November, the German drugmaker had said that 50 reported deaths were a "reasonable order of magnitude". The company on Saturday confirmed in a statement the new global number more than five times higher than the previous one, initially reported by magazines Der Spiegel and Die Zeit.
comments powered by